Research-Action in Hematology From Hospitalization to Home
NCT ID: NCT06053918
Last Updated: 2023-09-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
10 participants
OBSERVATIONAL
2019-05-07
2021-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
To study and support the hospitalization and the return home of patients with the help of a psychological follow-up started in a hospital institution and which will continue in the patient's home, based on the concepts of transitionality and narrativity.
Material and method To do this, the subjects will benefit from psychological interviews where they will freely discuss what concerns them, whether it is illness, treatment, returning home, or any other personal subject.
They will be divided into two groups of 5 patients each, one of the groups will benefit from follow-up in an institution as contracted for several years between the Institute of Hematology and the psychologists of the UMDSP, another from the same follow-up but with the presence of the psychologist at the time of discharge extended to the patient's home after leaving the hospital for a period of 2 months.
To ensure a certain consistency in the evaluation criteria, these will be standardized in the form of questionnaires completed blindly by the patient, a caregiver and the investigator, at 3 key times of the research (entry, discharge from hospital, two months after this discharge)
Device tested:
The aim of this work is to test the benefits of a device based on transitionality, which can limit, thanks to the restoration of the symbolization process, the deleterious effects of each of the stages imposed by the disease, the care and the resumption of autonomy once the active phase of care has passed.
Narrativity is also at the heart of this transitional device. It makes it possible to evoke the present experience of the patient in connection with future projects and in the continuity of past, potentially traumatic events. It opens onto a dynamic temporal perspective where the trauma freezes.
The whole process promotes the subjective reappropriation of the experience and a psychic well-being.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Implementation of a Return Home With a Hospitalization at Home or With a Home Health Care Provider From the Services of Oncopneumology, Oncology and Hematology of University Hospital of Strasbourg
NCT03217864
Evaluation of Chemotherapy-induced Cognitive Disorders During the Treatment of Hematological Malignancies
NCT07147621
Study of the Impact of Non-pharmacological Techniques on Cognitive Complaints in Cancer Patients
NCT05943301
Effects of a Neuroscience-based Technique on Cancer Patients Announced of a Palliative Disease Progression and Partners
NCT03652298
LOG-I - Impact Study of LOG-AFTER Software on Long-term Monitoring of Former Patients (LOG-I - LOG-Impact Study)
NCT06939322
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
classic follow-up (Group A)
Group A will benefit from the classic follow-up, as it has been contractualized for several years now between the UMDSP and the hematology sector. Namely a psychological follow-up in the patient's room during the hospitalization time, once a week, more if the patient is going through a difficult passage that requires closer support. This follow-up is spread over an approximate period of 6 weeks maximum, depending on the length of hospitalization
No interventions assigned to this group
Intervention group (Group B)
Group B will benefit from this same follow-up, to which will be added an interview when leaving the sector, and the extension of follow-up of the patient at home according to the same conditions: once a week, more if necessary, over a period of two months. This follow-up is spread over an approximate period of 15 weeks maximum, depending on the length of hospitalization.
additional follow-up extension at home
additional interview when leaving the sector, and the extension of follow-up of the patient at home
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
additional follow-up extension at home
additional interview when leaving the sector, and the extension of follow-up of the patient at home
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* patient with haematologic cancer
* patient requesting psychological assistance or accepting proposed psychological assistance
* signed informed consent
Exclusion Criteria
* patient not able to participate
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Caen
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CAEN University Hospital
Caen, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
18-199
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.